BIOABS Stock Overview Develops biological drugs for patients with disorders of the central nervous system in Sweden. More details
Rewards Risk Analysis See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
BioArctic AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for BioArctic Historical stock prices Current Share Price SEK 195.40 52 Week High SEK 195.40 52 Week Low SEK 151.75 Beta -0.26 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change n/a 5 Year Change 148.60% Change since IPO 563.50%
Recent News & Updates
BioArctic AB (publ) Announces Dosing of First Patient in EXIST Phase 2a Study in Parkinson's Disease Dec 05
Eisai Co., Ltd. and BioAge Labs, Inc. Announce CHMP Issues Positive Recommendation for Approval of Lecanemab in the EU Nov 15 BioArctic AB (publ) to Report Q2, 2025 Results on Aug 28, 2025
BioArctic AB (publ) Presents Nomination Committee Oct 13
BioArctic AB (publ), Annual General Meeting, May 22, 2025 Oct 12
BioArctic AB (publ) Announces Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology Aug 27 See more updates
BioArctic AB (publ) Announces Dosing of First Patient in EXIST Phase 2a Study in Parkinson's Disease Dec 05
Eisai Co., Ltd. and BioAge Labs, Inc. Announce CHMP Issues Positive Recommendation for Approval of Lecanemab in the EU Nov 15 BioArctic AB (publ) to Report Q2, 2025 Results on Aug 28, 2025
BioArctic AB (publ) Presents Nomination Committee Oct 13
BioArctic AB (publ), Annual General Meeting, May 22, 2025 Oct 12
BioArctic AB (publ) Announces Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology Aug 27
BioArctic AB (publ) Approves Leqembi [®] for the Treatment of Alzheimer's Disease in South Korea May 25
BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders Mar 14 The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab
BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI Oct 26
BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease Aug 24
Second quarter 2023 earnings released: kr1.16 loss per share (vs kr0.52 loss in 2Q 2022) Jul 13
Investor sentiment deteriorates as stock falls 16% Jul 04 BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024
Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea Jun 08
Vice President of Communications & IR recently sold kr1.7m worth of stock Jun 05
BioArctic AB (publ) Approves Board Changes Jun 02 Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease May 17
VP & Head of Research recently sold kr6.5m worth of stock May 15
Insider recently bought kr241k worth of stock Apr 30
First quarter 2023 earnings released Apr 29
Independent Director recently sold kr3.3m worth of stock Feb 09
BioArctic AB (publ) Announces Board Changes Feb 07
Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021) Feb 05
Bioarctic AB's (Publ) Partner Eisai Announces that European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Jan 28
Insufficient new directors Jan 26
BioArctic AB (publ) Announces Wenche Rolfsen Declines Re-Election to the Board Jan 20
Insufficient new directors Jan 11
BioArctic AB (publ) Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI for the Treatment of Alzheimer's Disease Jan 09
Bioarctic AB's (Publ) Partner Eisai Presents Results from lecanemab Confirmatory Phase 3 Clarity Ad Study Nov 22
BioArctic AB (publ) Expands Portfolio with Alpha-Synuclein Brain Transporter Project Nov 17
Insufficient new directors Nov 16
BioArctic develops New treatment for Gaucher's Disease Nov 09
Third quarter 2022 earnings released Oct 21
Insufficient new directors Oct 21 BioArctic AB (publ) to Report Q3, 2023 Results on Nov 08, 2023
BioArctic AB (publ), Annual General Meeting, Jun 01, 2023 Oct 18
Bioarctic Ab's (Publ) Announces Positive Topline Results for the Large Global Phase 3 Confirmatory Clarity Ad Study in 1,795 Subjects Sep 28
Insufficient new directors Sep 22
Bioarctic AB (Publ) Announces Latest Data on Lecanemab Presented At Alzheimer's Association International Conference (Aaic) Aug 05
Full year 2021 earnings released: kr1.36 loss per share (vs kr0.78 loss in FY 2020) Apr 06
Bioarctic AB Announces Executive Changes Feb 19
BioArctic AB (publ) to Report Fiscal Year 2021 Final Results on Mar 31, 2022 Feb 04
DIAN-TU Enrolls First Subject for the Tau Nexgen Study with Lecanemab as Back-Ground Anti-Amyloid Treatment Jan 19
Bioarctic AB (Publ) Announces Lecanemab Granted Fast Track Designation by the FDA Dec 25
Insufficient new directors Nov 04
BioArctic AB's partner Eisai Initiates Rolling Submission for the US FDA Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway Sep 29
BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Alzheimer's Disease May 12
Independent Director has left the company May 12 Shareholder Returns BIOABS GB Biotechs GB Market 7D 0% -2.5% 2.2% 1Y n/a -18.4% 13.7%
See full shareholder returns
Return vs Industry: Insufficient data to determine how BIOABS performed against the UK Biotechs industry .
Return vs Market: Insufficient data to determine how BIOABS performed against the UK Market .
Price Volatility Is BIOABS's price volatile compared to industry and market? BIOABS volatility BIOABS Average Weekly Movement n/a Biotechs Industry Average Movement 7.8% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.3% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: BIOABS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine BIOABS's volatility change over the past year.
About the Company BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain.
Show more BioArctic AB (publ) Fundamentals Summary How do BioArctic's earnings and revenue compare to its market cap? BIOABS fundamental statistics Market cap SEK 19.18b Earnings (TTM ) -SEK 232.86m Revenue (TTM ) SEK 167.14m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BIOABS income statement (TTM ) Revenue SEK 167.14m Cost of Revenue SEK 90.50m Gross Profit SEK 76.64m Other Expenses SEK 309.50m Earnings -SEK 232.86m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
Earnings per share (EPS) -2.63 Gross Margin 45.85% Net Profit Margin -139.32% Debt/Equity Ratio 0%
How did BIOABS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/12 02:23 End of Day Share Price 2024/11/26 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources BioArctic AB (publ) is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kristofer Liljeberg-Svensson Carnegie Investment Bank AB Patrik Ling DNB Markets Rajan Sharma Goldman Sachs
Show 4 more analysts 